Sentence: To investigate the cardiac safety of adjuvant Non-Pegylated Liposomal Doxorubicin ( NPL-DOX ) combined to Cyclophosphamide ( CTX ) and followed by weekly Paclitaxel , in older patients ( ≥65 years ) with diagnosis of high risk breast cancer .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Doxorubicin', 'Cyclophosphamide', 'Paclitaxel'], 'is_context_needed': True}]